Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/63763
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- IOC - Artigos de Periódicos [12982]
Metadata
Show full item record
DISTINCT ADVERSE REACTIONS TO MRNA, INACTIVATED VIRUS, AND ADENOVIRUS VECTOR COVID-19 VACCINES: INSIGHTS FROM A COHORT STUDY ON ATOPIC AND NON-ATOPIC SUBJECTS IN BRAZIL
Author
Affilliation
Federal University of Uberlândia. Institute of Biomedical Sciences. Laboratory of Allergy and Clinical Immunology. Uberlândia, MG, Brasil.
Federal University of Uberlândia. Institute of Biomedical Sciences. Laboratory of Allergy and Clinical Immunology. Uberlândia, MG, Brasil.
Federal University of Uberlândia. Institute of Biomedical Sciences. Laboratory of Allergy and Clinical Immunology. Uberlândia, MG, Brasil.
Federal University of Acre. Health and Sports Sciences Center. Laboratory of Translational Immunology. Rio Branco, AC, Brasil.
Federal University of Uberlândia. Institute of Biomedical Sciences. Laboratory of Allergy and Clinical Immunology. Uberlândia, MG, Brasil.
Federal University of Uberlândia. Institute of Biomedical Sciences. Laboratory of Allergy and Clinical Immunology. Uberlândia, MG, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil.
Federal University of Uberlândia. Institute of Biomedical Sciences. Laboratory of Allergy and Clinical Immunology. Uberlândia, MG, Brasil.
Federal University of Uberlândia. Institute of Biomedical Sciences. Laboratory of Allergy and Clinical Immunology. Uberlândia, MG, Brasil.
Federal University of Acre. Health and Sports Sciences Center. Laboratory of Translational Immunology. Rio Branco, AC, Brasil.
Federal University of Uberlândia. Institute of Biomedical Sciences. Laboratory of Allergy and Clinical Immunology. Uberlândia, MG, Brasil.
Federal University of Uberlândia. Institute of Biomedical Sciences. Laboratory of Allergy and Clinical Immunology. Uberlândia, MG, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil.
Abstract
The emergence of COVID-19 caused by SARS-CoV-2 prompted an unprecedented global response to develop vaccines at an accelerated pace. Messenger RNA (mRNA) and adenovirus vector vaccines emerged as the frontrunners in global immunization efforts, significantly reducing hospitalization, severity, and mortality, supplemented by inactivated virus-based vaccines in developing countries. However, concerns regarding adverse effects, including allergic reactions, have been raised. This study aimed to investigate the adverse effects following COVID-19 vaccination, particularly in atopic and non-atopic individuals. A cohort of 305 volunteers receiving BNT162, ChAdOx1, or CoronaVac vaccines were assessed based on a Skin Prick Test (SPT), specific IgE levels, and clinical history of asthma and rhinitis. Adverse effects were self-reported and scored across the different vaccination shots. The results indicated a notable presence of mild adverse effects following the first and third doses, regardless of vaccine type. ChAdOx1 recipients experienced more adverse effects compared to those receiving BNT162 and CoronaVac, including headaches, muscle pain, fever, chills, nausea, and flu-like symptoms. Atopic individuals receiving ChAdOx1 reported more adverse effects, such as muscle pain, fever, and chills, compared to non-atopic individuals. Conversely, headaches were more frequently reported in non-atopic individuals receiving BNT162 compared to atopic individuals. No anaphylaxis or allergic reactions were reported, indicating valuable evidence supporting the safety of COVID-19 vaccination in individuals with respiratory allergies. This study highlights the importance of understanding vaccine-related adverse effects, particularly in vulnerable populations, to inform vaccination strategies and address safety concerns in global immunization campaigns.
Share